Request Demo

Last update 08 May 2025

TUSC1

Last update 08 May 2025

Basic Info

Synonyms

CCDC89B, TSG-9, TSG9

+ [3]

Introduction-

Drugs associated with TUSC1

IN202211003978

Patent Mining

Target

TUSC1

Mechanism-

Active Org.

All India Institute of Medical Sciences [+1]

Originator Org.

Indian Council of Medical Research [+1]

Active Indication

Functional disorder [+2]

Inactive Indication-

Drug Highest PhaseDiscovery

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with TUSC1

100 Translational Medicine associated with TUSC1

0 Patents (Medical) associated with TUSC1

Literatures (Medical) associated with TUSC1

11 Aug 2023·Cancers

Relationship of Mitochondrial-Related Protein Expression with the Differentiation, Metastasis, and Poor Prognosis of Oral Squamous Cell Carcinoma.

Article

Author: Saito, Izumi ; Hirota, Junya ; Akashi, Masaya ; Arimoto, Satomi ; Kakei, Yasumasa ; Hasegawa, Takumi ; Amano-Iga, Rika ; Takeda, Daisuke ; Murakami, Aki ; Yatagai, Nanae

Mitochondrial dysfunction and respiratory function changes have been consistently associated with the initiation and progression of cancer. The purpose of this study was to retrospectively investigate the expression of mitochondrial tumor-suppressor and DNA-repair proteins in patients with oral squamous cell carcinoma (OSCC) and to evaluate the relationship between their expression and prognosis. We enrolled 197 patients with OSCC who underwent surgical resection between August 2013 and October 2018. Clinical, pathological, and epidemiological data were retrospectively collected from hospital records. The expression of peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α), mitochondrial transcription factor A, mitochondrial tumor suppressor gene 1, silent information regulator 3, and 8-hydroxyguanine DNA glycosylase was investigated using immunochemistry. The 3-year disease-specific survival (DSS) rates of patients showing positive expression of all selected proteins were significantly higher than those of patients showing a lack of expression. Multivariate analysis revealed that the expression of PGC-1α (hazard ratio, 4.684) and vascular invasion (hazard ratio, 5.690) can predict the DSS rate (p < 0.001). Low PGC-1α expression and vascular invasion are potential clinically effective predictors of the prognosis of OSCC.

01 Dec 2022·BMC Research Notes

Genome-wide linkage search for cancer susceptibility loci in a cohort of non BRCA1/2 families in Sri Lanka

Article

Author: Musolf, Anthony M ; Wijesiriwardhana, Prabhavi ; Dissanayake, Vajira H W ; Bailey-Wilson, Joan E ; Wetthasinghe, T Kalum

AbstractObjectiveAlthough linkage studies have been utilized for the identification of variants associated with cancer in the world, little is known about their role in non BRCA1/2 individuals in the Sri Lankans. Hence we performed linkage analysis to identify susceptibility loci related to the inherited risk of cancer in a cohort of Sri Lankans affected with hereditary breast cancer. The Illumina global screening array having 654,027 single nucleotide polymorphism markers was performed in four families, in which at least three individuals within third degree relatives were affected by breast cancer. Two-point parametric linkage analysis was conducted assuming disease allele frequency of 1%. Penetrance was set at 90% for carriers with a 10% phenocopy rate.ResultsThirty-one variants exhibited genome-wide suggestive HLODs. The top overall HLOD score was at rs1856277, an intronic variant in MYO16 on chromosome 13. The two most informative families also suggested several candidate linked loci in genes, including ERAP1, RPRM, WWOX, CDH1, EXOC1, HUS1B, STIM1 and TUSC1. This study provides the first step in identifying germline variants that may be involved in risk of cancer in cancer-aggregated non-BRCA1/2 families from the understudied Sri Lankan population. Several candidate linked regions showed suggestive evidence of linkage to cancer risk.

01 Jun 2022·Journal of Gastroenterology and HepatologyQ3 · MEDICINE

Circular RNA circ_0065378 upregulates tumor suppressor candidate 1 by competitively binding with miR‐4701‐5p to alleviate colorectal cancer progression

Q3 · MEDICINE

Article

Author: Liu, Yeliu ; Zhu, Xinguo ; Yan, Dongsheng ; Liu, Weidong

AbstractBackground and AimColorectal cancer (CRC), the third most lethal human cancer worldwide, seriously threatens human health and life. Numerous circular RNAs (circRNAs) including circ_PLXNB1 (hsa_circ_0065378) have been confirmed to be dysregulated in CRC by RNA‐seq analysis. We aimed to explore the functional role of circ_PLXNB1 in CRC malignant behaviors and clarify its potential molecular mechanism.MethodsGene expression levels of circ_PLXNB1 and miR‐4701‐5p were determined by quantitative real‐time polymerase chain reaction analysis. MTT and Transwell assays were conducted to measure cell proliferation, invasion, and migration. Protein expression of tumor suppressor candidate 1 (TUSC1), E‐cadherin and N‐cadherin was determined by western blot analysis. Mouse xenograft models were used to investigate the role of circ_PLXNB1 in tumor growth.ResultsThe results showed that gene expression of circ_PLXNB1 in CRC tissues was significantly downregulated. Overexpression of circ_PLXNB1 inhibited the malignant behaviors of CRC cells, as manifested by the decrease in cell proliferation, cell invasion, migration, and EMT. Mechanistically, circ_PLXNB1 exerted its functional effects by binding with miR‐4701‐5p. Moreover, TUSC1 siRNA partially abolished the suppressive effect of the miR‐4701‐5p inhibitor or circ_PLXNB1 on CRC cell malignant behaviors.ConclusionsCirc_PLXNB1 attenuated CRC progression by binding with miR‐4701‐5p to overexpress TUSC1, indicating that the circ_PLXNB1/miR‐4701‐5p/TUSC1 axis might be a potential novel molecular target in CRC diagnosis and therapy.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis